Replimune Group, Inc.

Replimune Group is a clinical-stage biotechnology company developing oncolytic immunotherapies designed to treat solid tumors by activating the immune system against cancer cells. The company's approach utilizes selectively replicating viruses engineered to express immunomodulatory proteins. The lead candidate, RP1, is a modified herpes simplex virus-1 (HSV-1) that expresses GALV-GP R(-) and human GM-CSF. The company is also advancing RP2, which expresses an anti-CTLA-4 antibody-like protein to block immune checkpoint inhibition, and RP3, designed to express immune-activating proteins that stimulate T cell responses.

As a clinical-stage company, Replimune has not yet commercialized products and does not generate revenue from product sales. The company operates primarily through research and development activities focused on advancing its oncolytic immunotherapy pipeline toward later-stage clinical trials.

Headquartered in Woburn, Massachusetts, Replimune operates with approximately 479 full-time employees. The company was incorporated in Delaware and is listed on the Nasdaq exchange with a market capitalization of approximately $0.6 billion.